Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin-angiotensin-aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study.
| dc.rights.license | open | en_US |
| dc.contributor.author | MOUSTAFA, Diala Alhaj | |
| dc.contributor.author | IMRAN, Zainab | |
| dc.contributor.author | ISMAIL, Roua | |
| dc.contributor.author | RAYAN, Menatallah | |
| hal.structure.identifier | Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases | |
| dc.contributor.author | GADEAU, Alain-Pierre | |
| dc.contributor.author | ELDASSOUKI, Hussein | |
| dc.contributor.author | ABDULRAHMAN, Nabeel | |
| dc.contributor.author | MRAICHE, Fatima | |
| dc.date.accessioned | 2023-01-16T15:08:19Z | |
| dc.date.available | 2023-01-16T15:08:19Z | |
| dc.date.issued | 2022-03-01 | |
| dc.identifier.issn | 1573-4978 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/171694 | |
| dc.description.abstractEn | Numerous studies demonstrate parallels between CVD, type 2 diabetes mellitus (T2DM) and COVID-19 pathology, which accentuate pre-existing complications in patients infected with COVID-19 and potentially exacerbate the infection course. Antidiabetic drugs such as sodium-glucose transporter-2 (SGLT-2) inhibitors have garnered substantial attention recently due to their efficacy in reducing the severity of cardiorenal disease. The effect of SGLT-2 inhibitors in patients with COVID-19 remains unclear particularly since SGLT-2 inhibitors contribute to altering the RAAS cascade activity, which includes ACE-2, the major cell entry receptor for SARS-CoV2. A study, DARE-19, was carried out to unveil the effects of SGLT-2 inhibitor treatment on comorbid disease complications and concomitant COVID-19 outcomes and demonstrated no statistical significance. However, the need for further studies is essential to provide conclusive clinical findings. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | Angiotensin-Converting Enzyme 2 | |
| dc.subject.en | Benzhydryl Compounds | |
| dc.subject.en | COVID-19 | |
| dc.subject.en | Clinical Trials | |
| dc.subject.en | Phase III as Topic | |
| dc.subject.en | Double-Blind Method | |
| dc.subject.en | Drug Repositioning | |
| dc.subject.en | Glucosides | |
| dc.subject.en | Heart Diseases | |
| dc.subject.en | Humans | |
| dc.subject.en | Kidney Diseases | |
| dc.subject.en | Mitochondria | |
| dc.subject.en | Multicenter Studies as Topic | |
| dc.subject.en | Oxidative Stress | |
| dc.subject.en | Randomized Controlled Trials as Topic | |
| dc.subject.en | Receptors | |
| dc.subject.en | Virus | |
| dc.subject.en | Renin-Angiotensin System | |
| dc.subject.en | Respiratory Insufficiency | |
| dc.subject.en | SARS-CoV-2 | |
| dc.subject.en | Sodium-Glucose Transporter 2 | |
| dc.subject.en | Sodium-Glucose Transporter 2 Inhibitors | |
| dc.title.en | Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin-angiotensin-aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study. | |
| dc.title.alternative | Mol Biol Rep | en_US |
| dc.type | Article de revue | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Médecine humaine et pathologie | en_US |
| dc.identifier.pubmed | 35102475 | en_US |
| bordeaux.journal | Molecular Biology Reports | en_US |
| bordeaux.page | 2321-2324 | en_US |
| bordeaux.volume | 49 | en_US |
| bordeaux.hal.laboratories | Biologie des maladies cardiovasculaires (BMC) - UMR 1034 | en_US |
| bordeaux.issue | 3 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.import.source | pubmed | |
| hal.export | false | |
| workflow.import.source | pubmed | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Molecular%20Biology%20Reports&rft.date=2022-03-01&rft.volume=49&rft.issue=3&rft.spage=2321-2324&rft.epage=2321-2324&rft.eissn=1573-4978&rft.issn=1573-4978&rft.au=MOUSTAFA,%20Diala%20Alhaj&IMRAN,%20Zainab&ISMAIL,%20Roua&RAYAN,%20Menatallah&GADEAU,%20Alain-Pierre&rft.genre=article |
